pp 1–7 | Cite as

The relationship between urotensin II and insulin resistance in women with gestational diabetes mellitus

  • Mehmet Calan
  • Tugba Arkan
  • Tuncay Kume
  • Fırat Bayraktar
Original Article



Urotensin II (UII), a pluripotent vasoactive peptide, plays a crucial role in development of insulin resistance. Gestational diabetes mellitus (GDM) is a metabolic disorder associated with insulin resistance. The aims of the current study were to compare UII levels in women with or without GDM and to investigate the relationship between UII and insulin resistance in women with GDM.


A total of 84 women were recruited in this case-control study (42 women with GDM and 42 age- and body mass index (BMI)-matched pregnant women without GDM as controls). GDM was diagnosed by a 2-h 75-g oral glucose tolerance test over a period of 24–28 gestational weeks. Circulating UII levels were assessed via the ELISA method. The metabolic parameters of the recruited women were also determined.


The circulating levels of UII in women with GDM were higher than in controls (11.56 ± 4.13 vs. 7.62 ± 3.45 ng/ml, P < 0.001). UII showed a positive correlation with insulin resistance marker (HOMA-IR), fasting blood glucose, and BMI. Moreover, according to the results of multiple linear regression analyses, UII was independently related to HOMA-IR. Additionally, the binary logistic analysis revealed that the women with the highest tertile of UII levels showed increased risk for GDM by comparison with those women with the lowest tertile of UII levels.


Elevated UII levels are associated with insulin resistance in women with GDM.


Gestational diabetes mellitus Urotensin II Insulin resistance Body mass index 



Body mass index


Confidence interval


Coefficient of variability


Diastolic blood pressure


Fasting blood glucose


High-density lipoprotein cholesterol


Homeostasis model assessment of insulin resistance


High-sensitivity C-reactive protein


Gestational diabetes mellitus


Low-density lipoprotein cholesterol


Oral glucose tolerance test


Odds ratio


Systolic blood pressure


Type 2 diabetes mellitus


Urotensin II


Variance inflation factor


Author contributions

M.C., T.A., T.K., and F.B. participated in the study design and T.K. and M.C. performed ELISA. M.C., T.A., T.K., and F.B. participated in the study design, analyzed the data, and wrote, reviewed, and edited the manuscript. M.C., F.B., and T.A. provided serum samples and contributed to discussions of data interpretation. All authors reviewed and edited the manuscript. M.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Compliance with ethical standards

The subjects gave their oral and written informed consent before their inclusion in the study. The study adhered strictly to the principles of the Declaration of Helsinki as revised in 2008.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Fadl HE, Ostlund IKM, Magnuson AFK, Hanson USB (2010) Maternal and neonatal outcomes and time trends of gestational diabetes mellitus in Sweden from 1991 to 2003. Diabet Med 27:436–441CrossRefGoogle Scholar
  2. 2.
    Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, Hod M, Kitzmiller JL, Kjos SL, Oats JN, Pettitt DJ, Sacks DA, Zoupas C (2007) Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 30(Suppl 2):S251–S260CrossRefGoogle Scholar
  3. 3.
    Kim C, Newton KM, Knopp RH (2002) Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 25:1862–1868CrossRefGoogle Scholar
  4. 4.
    Desoye G, Hauguel-de Mouzon S (2007) The human placenta in gestational diabetes mellitus: the insulin and cytokine network. Diabetes Care 30:S120–S126CrossRefGoogle Scholar
  5. 5.
    Kirwan JP, Hauguel-De Mouzon S, Lepercq J, Challier J-C, Huston-Presley L, Friedman JE, Kalhan SC, Catalano PM (2002) TNF- is a predictor of insulin resistance in human pregnancy. Diabetes 51:2207–2213CrossRefGoogle Scholar
  6. 6.
    Tumurbaatar B, Poole AT, Olson G, Makhlouf M, Sallam HS, Thukuntla S, Kankanala S, Ekhaese O, Gomez G, Chandalia M, Abate N (2017) Adipose tissue insulin resistance in gestational diabetes. Metab Syndr Relat Disord 15:86–92CrossRefGoogle Scholar
  7. 7.
    Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, Catalano P (1999) Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes 48:1807–1814CrossRefGoogle Scholar
  8. 8.
    Gruson D, Rousseau MF, Ketelslegers J-M, Hermans MP (2010) Raised plasma urotensin II in type 2 diabetes patients is associated with the metabolic syndrome phenotype. J Clin Hypertens (Greenwich) 12:653–660CrossRefGoogle Scholar
  9. 9.
    Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282–286CrossRefGoogle Scholar
  10. 10.
    Li Y, Zhao S, Wang Y, Chen Y, Lin Y, Zhu N, Zheng H, Wu M, Cheng D, Li Y, Bai L, Fan J, Liu E (2014) Urotensin II promotes atherosclerosis in cholesterol-fed rabbits. PLoS One 9:e95089CrossRefGoogle Scholar
  11. 11.
    Li Y-Y, Shi Z-M, Yu X-Y, Feng P, Wang X-J (2016) Urotensin II-induced insulin resistance is mediated by NADPH oxidase-derived reactive oxygen species in HepG2 cells. World J Gastroenterol 22:5769CrossRefGoogle Scholar
  12. 12.
    Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N, Hirata Y (2001) Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens 19:2185–2190CrossRefGoogle Scholar
  13. 13.
    Vaudry H, Do Rego J-C, Le Mevel J-C, Chatenet D, Tostivint H, Fournier A, Tonon M-C, Pelletier G, Conlon JM, Leprince J (2010) Urotensin II, from fish to human. Ann N Y Acad Sci 1200:53–66CrossRefGoogle Scholar
  14. 14.
    Yilmaz Ö, Calan O, Kume T, Calan M (2013) The relationship of urotensin II with insulin resistance and hs-CRP in patients having PCOS. Gynecol Endocrinol 29:970–973CrossRefGoogle Scholar
  15. 15.
    Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O (2003) Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 104:1–5CrossRefGoogle Scholar
  16. 16.
    Cheung BMY, Leung R, Man YB, Wong LYF (2004) Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22:1341–1344CrossRefGoogle Scholar
  17. 17.
    International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, de Leiva A, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJN, Omori Y, Schmidt MI (2010) International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676–682CrossRefGoogle Scholar
  18. 18.
    Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMedPubMedCentralGoogle Scholar
  19. 19.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefGoogle Scholar
  20. 20.
    Ryan EA, O’Sullivan MJ, Skyler JS (1985) Insulin action during pregnancy: studies with the euglycemic clamp technique. Diabetes 34:380–389CrossRefGoogle Scholar
  21. 21.
    Shao J, Yamashita H, Qiao L, Draznin B, Friedman JE (2002) Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus. Diabetes 51:19–29CrossRefGoogle Scholar
  22. 22.
    Fasshauer M, Blüher M, Stumvoll M (2014) Adipokines in gestational diabetes. Lancet Diabetes Endocrinol 2:488–499CrossRefGoogle Scholar
  23. 23.
    Suguro T, Watanabe T, Ban Y, Kodate S, Misaki A, Hirano T, Miyazaki A, ADACHI M (2007) Increased human urotensin II levels are correlated with carotid atherosclerosis in essential hypertension. Am J Hypertens 20:211–217CrossRefGoogle Scholar
  24. 24.
    Huristoglu M, Ekiz A, Mete F, Okuturlar Y, Kocoglu H, Dumanli G, Cakirca M, Anataca G, Kuru O, Dogan S, Pehlivan B, Tabak O, Yildirim G, Dogan H, Erismis B (2017) Plasma urotensin II concentration in gestational diabetes. Arch Clin Exp MedGoogle Scholar
  25. 25.
    Wenyi Z, Suzuki S, Hirai M, Hinokio Y, Tanizawa Y, Matsutani A, Satoh J, Oka Y (2003) Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 46:972–976CrossRefGoogle Scholar
  26. 26.
    Okumus S, Igci YZ, Taskin T, Oztuzcu S, Gurler B, Eslik Z, Gogebakan B, Coskun E, Erbagci I, Demiryurek S, Cengiz B, Demiryurek AT (2012) Association between Thr21Met and Ser89Asn polymorphisms of the urotensin-II (UTS2) gene, diabetes mellitus, and diabetic retinopathy. Curr Eye Res 37:921–929CrossRefGoogle Scholar
  27. 27.
    Suzuki S, Wenyi Z, Hirai M, Hinokio Y, Suzuki C, Yamada T, Yoshizumi S, Suzuki M, Tanizawa Y, Matsutani A, Oka Y (2004) Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 25:1803–1808CrossRefGoogle Scholar
  28. 28.
    Abell S, De Courten B, Boyle J, Teede H (2015) Inflammatory and other biomarkers: role in pathophysiology and prediction of gestational diabetes mellitus. Int J Mol Sci 16:13442–13473CrossRefGoogle Scholar
  29. 29.
    Watanabe T, Kanome T, Miyazaki A, Katagiri T (2006) Human urotensin II as a link between hypertension and coronary artery disease. Hypertens Res 29:375–387CrossRefGoogle Scholar
  30. 30.
    Cadirci E, Halici Z, Yayla M, Toktay E, Bayir Y, Karakus E, Topcu A, Buyuk B, Albayrak A (2016) Blocking of urotensin receptors as new target for treatment of carrageenan induced inflammation in rats. Peptides 82:35–43CrossRefGoogle Scholar
  31. 31.
    Albertin G, Guidolin D, Sorato E, Oselladore B, Tortorella C, Ribatti D (2011) Urotensin-II-stimulated expression of pro-angiogenic factors in human vascular endothelial cells. Regul Pept 172:16–22CrossRefGoogle Scholar
  32. 32.
    Sheridan MA, Plisetskaya EM, Bern HA, Gorbman A (1987) Effects of somatostatin-25 and urotensin II on lipid and carbohydrate metabolism of coho salmon, Oncorhynchus kisutch. Gen Comp Endocrinol 66:405–414CrossRefGoogle Scholar
  33. 33.
    Kiss RS, You Z, Genest J, Behm DJ, Giaid A (2011) Urotensin II differentially regulates macrophage and hepatic cholesterol homeostasis. Peptides 32:956–963CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018

Authors and Affiliations

  • Mehmet Calan
    • 1
  • Tugba Arkan
    • 2
  • Tuncay Kume
    • 3
  • Fırat Bayraktar
    • 2
  1. 1.Division of Endocrinology and Metabolism, Department of Internal MedicineIzmir Bozyaka Training and Research HospitalIzmirTurkey
  2. 2.Division of Endocrinology and Metabolism, Department of Internal MedicineDokuz Eylul University Medical SchoolIzmirTurkey
  3. 3.Department of Biochemistry and Clinical BiochemistryDokuz Eylul University Medical SchoolIzmirTurkey

Personalised recommendations